No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 9.3x · 10Y median 8.5x · 72nd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:11.047Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for CeriBell, Inc. (CBLL) stock was $24.86 as of Oct 5, 2026, 4:00 PM EDT, up 4.94% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +96.0%
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside.
Medical - Devices · Sunnyvale, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.50
Revenue Est.
$29.17M
Last Quarter Results
EPS
$-0.40
vs Estimate
$-0.46
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CBLL | $943.26M | $24.86 | +4.94% | +96.04% | N/A | N/A | N/A |
| 2KURA | $942.78M | $10.62 | -0.28% | +10.92% | -10.73% | +5.98% | vs CBLL |
| 3ABUS | $922.50M | $4.67 | +4.94% | +6.59% | +2.19% | +2.93% | vs CBLL |
| 4HSTM | $921.45M | $31.54 | +2.34% | +15.84% | +2.34% | +1.25% | vs CBLL |
| 5BVS | $915.95M | $13.52 | +2.97% | +91.99% | -0.81% | N/A | vs CBLL |
| 6CRVS | $903.13M | $10.74 | -1.47% | +49.09% | +17.88% | -4.26% | vs CBLL |
forward FY estimate
N/A
$28.10M
vs Estimate
$27.28M
Consensus Rating
Based on 7 analysts
Average Price Target
$28.57
+14.9% upside
Low
$24.00
Current
$24.86
High
$33.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.56 | $-0.51 | $-0.46 | 4 |
| Quarter ending Dec 2026 | $-0.46 | $-0.44 | $-0.42 | 4 |
| Quarter ending Mar 2027 | $-0.43 | $-0.43 | $-0.42 | 1 |
| Quarter ending Jun 2027 | $-0.42 | $-0.42 | $-0.41 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.07 | $-1.97 | $-1.88 | 6 |
| FY 2027 | $-1.81 | $-1.61 | $-1.29 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $28.82M | $29.17M | $29.53M | 5 |
| Quarter ending Dec 2026 | $31.68M | $31.73M | $31.78M | 5 |
| Quarter ending Mar 2027 | $33.63M | $34.10M | $34.28M | 4 |
| Quarter ending Jun 2027 | $35.36M | $35.85M | $36.04M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $115.19M | $115.54M | $115.89M | 6 |
| FY 2027 | $146.31M | $147.10M | $147.81M | 6 |
